Protocol Ledger

NCT05789524 · Phase II · TERMINATED

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Interventional Phase II clinical trial protocol NCT05789524 sponsored by ApcinteX in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-06 Enrollment: 60 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05789524
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05789524
Protocol FieldVerified Registry Value
NCT IdentifierNCT05789524
Consolidated Lead SponsorApcinteX
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment60 participants (ACTUAL)
Registered Start Date2023-07-06
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI